Medical devices, healthcare technology and the business of care
PMA approval · P250004

MMR IHC Panel pharmDx (Dako Omnis)

Agilent Technologies, Inc. · Decision date Aug 15, 2025

FDA DECISIONP250004

What did the FDA approve?

FDA records P250004 as an original PMA application. The recorded decision is approval, dated Aug 15, 2025.

FDA approval order statement

For In Vitro Diagnostic Use.MMR IHC Panel pharmDx (Dako Omnis) is a qualitative immunohistochemical (IHC) assay intended for use in the assessment of mismatch repair (MMR) proteins (MLH1, PMS2, MSH2, and MSH6) in formalin-fixed, paraffin-embedded (FFPE) colorectal cancer (CRC) tissue using EnVision FLEX visualization system on Dako Omnis automated staining instrument. MMR IHC Panel pharmDx (Dako Omnis) consists of MLH1 IHC pharmDx (Dako Omnis), PMS2 IHC pharmDx (Dako Omnis), MSH2 IHC pharmDx (Dako Omnis), and MSH6 IHC pharmDx (Dako Omnis), which must be used together to identify MMR deficient CRC patients.MMR IHC Panel pharmDx (Dako Omnis) is indicated as an aid to identify MMR deficient CRC patients eligible for treatment with OPDIVO (nivolumab) alone or OPDIVO (nivolumab) in combination with YERVOY (ipilimumab).
Regulatory pathway
Original PMA
Clinical specialty
Pathology
Decision date
Aug 15, 2025

FDA source record

Regulatory record facts

Identifier
P250004
Regulatory pathway
Premarket approval application
Product code
QNH
Decision code
APPR
Decision date
Aug 15, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Immunohistochemistry test, DNA mismatch repair (MMR) Protein assay.

Product code
QNH
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P250004 received

    Application receipt date recorded by FDA.

  2. P250004 · FDA decision

    APPR

  3. P250004/S001 · Related supplement

    MMR IHC Panel pharmDx (Dako Omnis)

Timeline entries are records held by MedtechLedger for P250004. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P250004

Product / regulatory recordCompanyPathwayDecision dateSource
Agilent Technologies, Inc.PMA supplementSep 11, 2026FDA

Explore the linked device profile

Other records with product code QNH

Product / regulatory recordCompanyPathwayDecision dateSource
Ventana Medical SystemsPMA supplementOct 8, 2026FDA
Ventana Medical Systems, Inc. (Roche Tissue Diagnostics)PMA supplementOct 8, 2026FDA
Ventana Medical Systems, Inc. (Roche Tissue Diagnostics)PMA approvalAug 17, 2021FDA
Ventana Medical SystemsPMA approvalApr 22, 2021FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Agilent Technologies, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
6392 Via Real, Carpinteria, CA, 93013

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records